Concepedia

Author

Carol S. Portlock

Memorial Sloan Kettering Cancer Center

Also Known As

C Portlock, C S Portlock, CAROL PORTLOCK, CAROL S. PORTLOCK, Carol Portlock, Carol S Portlock, Carol S. Portlock, Vijai, Joseph

182

Publications

8.4K

Citations

46

H-Index

87

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterCornell UniversityStanford UniversityYale UniversityNational Cancer Institute
CS

About

Carol S. Portlock is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

31

2.4K

2

Health Sciences

11

11

1.1K

3

Cellular Therapies

3

3

146

4

Education

1

1

24

5

Engineering

1

1

71

Carol S. Portlock

×

83

Publications

7.9K

Citations

44

H-Index

YearCitations

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy,

Journal of Clinical Oncology

2004

579

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz,

Blood

2001

423

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer,

Blood

2004

403

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz,

Journal of Clinical Oncology

2005

402

Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Kenneth Offit, Francesco Lo‐Coco, Diane C. Louie,

New England Journal of Medicine

1994

378

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein,

Journal of Clinical Oncology

2010

324

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Craig H. Moskowitz, Joseph R. Bertino, Jill R. Glassman,

Journal of Clinical Oncology

1999

302

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matthew J. Matasar, Andrew D. Zelenetz,

Blood

2011

280

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

David J. Straus, Carol S. Portlock, Jing Qin,

Blood

2004

278

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom,

The Lancet Oncology

2015

263

Page 1